ClinicalTrials.gov
ClinicalTrials.gov Menu

Phase 2 Anastrozole and Vandetanib (ZD6474) in Neoadjuvant Treatment of Postmenopausal Hormone Receptor-Positive Breast Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00481845
Recruitment Status : Terminated (Low accrual)
First Posted : June 4, 2007
Results First Posted : February 7, 2017
Last Update Posted : February 7, 2017
Sponsor:
Collaborator:
AstraZeneca
Information provided by (Responsible Party):
Mark Pegram, Stanford University

Study Type: Interventional
Study Design: Allocation: Randomized;   Intervention Model: Parallel Assignment;   Masking: None (Open Label);   Primary Purpose: Treatment
Condition: Breast Cancer
Interventions: Drug: Vandetanib
Drug: Anastrozole

  Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
No text entered.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
No text entered.

Reporting Groups
  Description
Vandetanib + Anastrozole Vandetanib and Anastrozole as neoadjuvant therapy
Anastrozole Anastrozole as neoadjuvant therapy

Participant Flow:   Overall Study
    Vandetanib + Anastrozole   Anastrozole
STARTED   1   0 
COMPLETED   1   0 
NOT COMPLETED   0   0 



  Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups
  Description
Vandetanib + Anastrozole Vandetanib and Anastrozole as neoadjuvant therapy
Anastrozole Anastrozole as neoadjuvant therapy
Total Total of all reporting groups

Baseline Measures
   Vandetanib + Anastrozole   Anastrozole   Total 
Overall Participants Analyzed 
[Units: Participants]
 1   0   1 
Age 
[Units: Participants]
Count of Participants
     
<=18 years      0   0.0%   0      0   0.0% 
Between 18 and 65 years      1 100.0%   0      1 100.0% 
>=65 years      0   0.0%   0      0   0.0% 
Gender 
[Units: Participants]
Count of Participants
     
Female      1 100.0%   0      1 100.0% 
Male      0   0.0%   0      0   0.0% 
Ethnicity (NIH/OMB) 
[Units: Participants]
Count of Participants
     
Hispanic or Latino      0   0.0%   0      0   0.0% 
Not Hispanic or Latino      1 100.0%   0      1 100.0% 
Unknown or Not Reported      0   0.0%   0      0   0.0% 
Race (NIH/OMB) 
[Units: Participants]
Count of Participants
     
American Indian or Alaska Native      0   0.0%   0      0   0.0% 
Asian      0   0.0%   0      0   0.0% 
Native Hawaiian or Other Pacific Islander      0   0.0%   0      0   0.0% 
Black or African American      0   0.0%   0      0   0.0% 
White      1 100.0%   0      1 100.0% 
More than one race      0   0.0%   0      0   0.0% 
Unknown or Not Reported      0   0.0%   0      0   0.0% 


  Outcome Measures

1.  Primary:   Tumor Objective Response by MRI   [ Time Frame: 1 year ]

2.  Secondary:   Pathologic Complete Response   [ Time Frame: 1 year ]


  Serious Adverse Events


  Other Adverse Events


  Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.


  More Information

Certain Agreements:  
Principal Investigators are NOT employed by the organization sponsoring the study.
There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.


Results Point of Contact:  
Name/Title: Mark Daniel Pegram; Susy Yuan-Huey Hung Professor
Organization: Stanford Cancer Institute, Stanford University
phone: 650-723-5801
e-mail: mpegram@stanford.edu



Responsible Party: Mark Pegram, Stanford University
ClinicalTrials.gov Identifier: NCT00481845     History of Changes
Other Study ID Numbers: IRB-08051
BRSADJ0008 ( Other Identifier: OnCore )
97923 ( Other Identifier: Stanford University Alternate IRB Approval Number )
First Submitted: May 31, 2007
First Posted: June 4, 2007
Results First Submitted: December 13, 2016
Results First Posted: February 7, 2017
Last Update Posted: February 7, 2017